{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:14:00Z","timestamp":1775870040953,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The poor prognosis of anaplastic thyroid cancer (ATC) patients is associated with limited effective therapeutic strategies. Multiple antiangiogenesis tyrosine kinase inhibitors (TKIs) have been applied in later-line treatment of ATC; however, the results reported in clinical trials were controversial. In this study, we reconstructed the patient-level data to pooled-analyze the survival data, responses, and adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Online databases (PubMed, Web of Science, Embase, and Cochrane CENTRAL) were searched on September 03, 2023. R software combined with the \u201cmetaSurvival\u201d and \u201cmeta\u201d packages were used to reconstruct the survival curves and summarize the response rates. The primary endpoints were progression-free survival (PFS) and overall survival (OS). The secondary endpoints were survival rate, objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Six prospective clinical trials involving 140 ATC patients were enrolled. Four types of TKIs (imatinib, pazopanib, sorafenib, and lenvatinib) were included. When advanced ATC patients were treated with the TKIs, the median OS was 4.8 months and the median PFS was 2.6 months. The pooled ORR and DCR were 9% and 53%. Hypertension, decreased appetite, rash, and lymphopenia were the most common grade\u2005\u2265\u20053 treatment-related adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Mono-anitangiogenesis TKI therapy showed limited improvements in treating advanced ATC patients. Combining antiangiogenesis TKI therapy with chemotherapy, radiotherapy, or immunotherapy could be the direction of future studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000038679","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T17:37:02Z","timestamp":1722620222000},"page":"e38679","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The efficacy and safety of antiangiogenesis tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: A meta-analysis of prospective studies"],"prefix":"10.1097","volume":"103","author":[{"given":"Ru-Bo","family":"Cao","sequence":"first","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Ge","sequence":"additional","affiliation":[{"name":"Wuhan Mental Health Center, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Xuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-He","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, the Second Affiliated Hospital of Anhui Medical University, Hefei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Hua","family":"Kuang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-7721","authenticated-orcid":false,"given":"Bi-Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers15010179","article-title":"Targeted therapy for anaplastic thyroid carcinoma: advances and management.","volume":"15","author":"Yuan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ctrv.2015.06.005","article-title":"PI3K\/Akt\/mTOR: a promising therapeutic target for non-medullary thyroid carcinoma.","volume":"41","author":"Petrulea","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"bvab102","DOI":"10.1210\/jendso\/bvab102","article-title":"Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR signaling axis in anaplastic thyroid cancer via genomic mechanisms.","volume":"5","author":"Davidson","year":"2021","journal-title":"J Endocr Soc"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.onc.1209899","article-title":"A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity.","volume":"26","author":"Yu","year":"2007","journal-title":"Oncogene"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1002\/ijc.25304","article-title":"BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.","volume":"127","author":"Liu","year":"2010","journal-title":"Int J Cancer"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"S1299","DOI":"10.1016\/j.annonc.2022.07.1735","article-title":"1655P Dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer.","volume":"33","author":"Jeon","year":"2022","journal-title":"Ann Oncol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/ERC-22-0022","article-title":"Effects of dabrafenib and erlotinib combination on treatment on anaplastic thyroid carcinoma.","volume":"29","author":"Choi","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1089\/thy.2019.0477","article-title":"Response to RET-specific therapy in RET fusion-positive anaplastic thyroid carcinoma.","volume":"30","author":"Dias-Santagata","year":"2020","journal-title":"Thyroid"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","article-title":"Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II Study.","volume":"24","author":"Hanna","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"920857","DOI":"10.3389\/fendo.2022.920857","article-title":"Efficacy and safety of lenvatinib in anaplastic thyroid carcinoma: a meta-analysis.","volume":"13","author":"Huang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/ERC-19-0011","article-title":"PI3K\/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.","volume":"26","author":"Wong","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1345203","DOI":"10.3389\/fendo.2024.1345203","article-title":"Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies.","volume":"15","author":"Kuang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.","volume":"350","author":"Shamseer","year":"2015","journal-title":"Bmj"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/thy.2010.0057","article-title":"A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.","volume":"20","author":"Ha","year":"2010","journal-title":"Thyroid"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2012-1520","article-title":"A multi-institutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.","volume":"97","author":"Bible","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/thy.2012.0103","article-title":"Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.","volume":"23","author":"Savvides","year":"2013","journal-title":"Thyroid"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer.","volume":"7","author":"Tahara","year":"2017","journal-title":"Front Oncol"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer.","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE).","volume":"173","author":"Higashiyama","year":"2022","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/cells10051082","article-title":"The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy.","volume":"10","author":"Singh","year":"2021","journal-title":"Cells"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"S1295","DOI":"10.1016\/j.annonc.2022.07.1726","article-title":"Phase II ATLEP trial: Final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma.","volume":"33","author":"Dierks","year":"2022","journal-title":"Ann Oncol"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1089\/thy.2022.0050","article-title":"A Pilot Study of Durvalumab (MEDI4736) with tremelimumab in combination with image-guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer.","volume":"32","author":"Lee","year":"2022","journal-title":"Thyroid"},{"key":"R25-20250503","first-page":"903","article-title":"Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer.","volume":"7","author":"Jing","year":"2017","journal-title":"Am J Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:12:50Z","timestamp":1746317570000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":25,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038679","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]}}}